Skip to main content
OpenTrials

Clinical trial condition

Hepatocellular Carcinoma (HCC)

Explore clinical trials studying Hepatocellular Carcinoma (HCC). Study availability and eligibility vary by location and protocol.

230 public trials 90 recruiting studies
Refine in advanced search Browse all conditions

Hepatocellular Carcinoma (HCC) trial results

Recruiting

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

NCT07291076

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +9 more
Locations
  • Local Institution - 0137 Duarte, California, United States
  • Local Institution - 0070 Los Angeles, California, United States
  • Local Institution - 0107 Chicago, Illinois, United States
  • Local Institution - 0134 Detroit, Michigan, United States
View all 64 locations
View Trial Details
Recruiting

A Phase 1 Study of the Safety and Tolerability of CTX-10726

NCT07419841

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +28 more
Locations
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Nebraska Cancer Specialists Omaha, Nebraska, United States
  • START New York Lake Success, New York, United States
  • UPMC Hillman Cancer Center Pittsburgh, Pennsylvania, United States
View Trial Details
Recruiting

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

NCT04634357

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +14 more
Locations
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Children's Hospital Orange County Orange, California, United States
  • UCSF Benioff Children's Hospitals San Francisco, California, United States
  • Dana-Farber/Boston Children's Cancer and Blood Disorders Center Boston, Massachusetts, United States
View Trial Details
Recruiting

Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors

NCT05176483

Conditions
Adenocarcinoma, Bronchial Neoplasms, Carcinoma, +47 more
Locations
  • Exelixis Clinical Site #67 Phoenix, Arizona, United States
  • Exelixis Clinical Site #1 Tucson, Arizona, United States
  • Exelixis Clinical Site #123 Palo Alto, California, United States
  • Exelixis Clinical Site #59 Santa Barbara, California, United States
View all 122 locations
View Trial Details
Recruiting

A Phase I, First in Human Study of CBA-1205, Anti-DLK1 Monoclonal Antibody in Patients With Advanced Solid Tumors, Hepatocellular Carcinoma (HCC), Melanoma, and Pediatric Cancer

NCT06636435

Conditions
Adenocarcinoma, Carcinoma, Carcinoma, Hepatocellular, +21 more
Locations
  • National Cancer Center Hospital East Kashiwa, Chiba, Japan
  • Kanagawa Cancer Center Yokohama, Kanagawa, Japan
  • Niigata University Medical and Dental Hospital Niigata, Japan
  • National Cancer Center Hospital Chūō, Tokyo, Japan
View Trial Details

Related conditions